Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Erectile Dysfunction 4Pancreatic Neoplasms 3Head and Neck Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Carcinoma 2Adenocarcinoma 2Urogenital Neoplasms 1Urinary Incontinence 1Sexual Dysfunction, Physiological 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Glioblastoma 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1Abdominal Cancer 1

Interventions

Paclitaxel 7Oxaliplatin 6Vincristine 4Radiotherapy 4Leucovorin 4Carboplatin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Fluorouracil 3Cytarabine 3xaliproden 2glucarpidase 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Prednisolone 2Magnesium Sulfate 2Duloxetine Hydrochloride 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurotoxicity Syndromes × Tadalafil × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡